mortality/aging
• no mice born
|
homeostasis/metabolism
• 30% reduction in formate level in E11.5 embryos
|
• decreased levels of free carnitine and specific acylcarnitines in E11.5 embryos
|
• elevated levels of specific acylcarnitines in E11.5 embryos
|
• significant increase in DHF, THF, CH-THF and CH2-THF levels in E11.5 embryos, partially mitigated by maternal sodium formate administration
• significant decrease in CH3-THF levels in E11.5 embryos, partially mitigated by maternal sodium formate administration
|
• 3x increase in E11.5 embryos
|
• in E11.5 embryos
|
growth/size/body
• severe in E11.5 embryos
|
embryo
• severe in E11.5 embryos
|
• in E11.5 embryos, partially mitigated by maternal sodium formate administration
|
nervous system
• in E11.5 embryos, partially mitigated by maternal sodium formate administration
|
exencephaly
(
J:338257
)
• in E11.5 embryos, partially mitigated by maternal sodium formate administration
|